Riverbridge Partners LLC Sells 13,973 Shares of Align Technology, Inc. $ALGN

Riverbridge Partners LLC reduced its position in Align Technology, Inc. (NASDAQ:ALGN) by 6.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 213,575 shares of the medical equipment provider’s stock after selling 13,973 shares during the quarter. Riverbridge Partners LLC owned about 0.29% of Align Technology worth $40,436,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ALGN. Ninety One UK Ltd boosted its position in shares of Align Technology by 58.7% in the first quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock valued at $307,800,000 after acquiring an additional 716,954 shares during the period. Federated Hermes Inc. lifted its position in Align Technology by 510.3% during the first quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider’s stock valued at $112,396,000 after purchasing an additional 591,588 shares during the last quarter. Mackenzie Financial Corp lifted its position in Align Technology by 4,217.3% during the first quarter. Mackenzie Financial Corp now owns 426,205 shares of the medical equipment provider’s stock valued at $67,707,000 after purchasing an additional 416,333 shares during the last quarter. AQR Capital Management LLC lifted its position in Align Technology by 104.2% during the first quarter. AQR Capital Management LLC now owns 404,310 shares of the medical equipment provider’s stock valued at $63,133,000 after purchasing an additional 206,308 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Align Technology by 32.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock valued at $132,221,000 after purchasing an additional 202,616 shares during the last quarter. 88.43% of the stock is currently owned by institutional investors.

Align Technology Stock Performance

ALGN stock opened at $128.18 on Thursday. The company has a market capitalization of $9.29 billion, a PE ratio of 21.62, a price-to-earnings-growth ratio of 1.45 and a beta of 1.65. Align Technology, Inc. has a one year low of $127.62 and a one year high of $259.01. The company’s 50 day moving average price is $149.94 and its two-hundred day moving average price is $167.53.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.08). The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The company’s revenue was down 1.6% compared to the same quarter last year. During the same period last year, the business posted $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. On average, research analysts predict that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology declared that its Board of Directors has approved a stock repurchase program on Tuesday, August 5th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at Align Technology

In other news, CEO Joseph M. Hogan bought 7,576 shares of the firm’s stock in a transaction that occurred on Friday, August 1st. The shares were bought at an average cost of $131.49 per share, with a total value of $996,168.24. Following the completion of the purchase, the chief executive officer directly owned 184,945 shares in the company, valued at $24,318,418.05. This represents a 4.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 0.66% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on ALGN shares. Morgan Stanley reiterated an “equal weight” rating and set a $154.00 target price (down from $249.00) on shares of Align Technology in a research report on Thursday, July 31st. Piper Sandler dropped their target price on shares of Align Technology from $250.00 to $190.00 and set an “overweight” rating for the company in a research report on Thursday, July 31st. Stifel Nicolaus dropped their target price on shares of Align Technology from $275.00 to $200.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Zacks Research lowered shares of Align Technology from a “hold” rating to a “strong sell” rating in a research report on Monday, September 1st. Finally, Wells Fargo & Company dropped their target price on shares of Align Technology from $246.00 to $199.00 and set an “overweight” rating for the company in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Align Technology presently has an average rating of “Moderate Buy” and a consensus target price of $215.00.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.